News & Events about Geron Corporation.
StockNews.com upgraded shares of Geron (NASDAQ:GERN Get Rating) to a sell rating in a report released on Thursday morning. Other analysts have also issued reports about the stock. Wedbush increased their price objective on shares of Geron from $5.00 to $6.00 and gave the stock an outperform ...
NEW YORK, Jan. 16, 2023 (GLOBE NEWSWIRE) -- UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA JULIA JUNGE and RICHARD JUNGE, on behalf ofthemselves and a class of similarly situated investors, Plaintiffs, v.GERON CORPORATION and JOHN A. SCARLETT, Defendants. Case No.: 3:20-cv-00547-WHA (...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Gerons Chairman and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the B. Riley Securities 3rd Annual Virtual Oncology Conference on...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today highlighted multiple additions to its senior commercial leadership team, as it prepares for the potential commercialization in the U.S. market of imetelstat, a first-in-class telomerase inhibitor. Key additions...